Antonilli 2016.

Methods	Uncontrolled phase I/II
Participants	14 high‐risk, disease‐free ovarian cancer (n = 7) or breast carcinoma participants + 3 recurrent OC patients vaccinated for compassionate use
Interventions	Triple peptide (MUC1, ErbB2, and CEA) with Montanide vaccine
Outcomes	Safety Immune response Clinical response
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Uncontrolled trial
Allocation concealment (selection bias)	High risk	Uncontrolled trial
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not explicitly stipulated
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not explicitly stipulated
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants included in analysis
Selective reporting (reporting bias)	Unclear risk	Study protocol not publicly available
Other bias	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’